Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

David Ewing Duncan

A View from David Ewing Duncan

Where Have All the Billions Gone?

Big Pharma is on a buying spree to obtain smaller biotech companies after having spent billions on R&D and failing to produce new drugs.

  • April 24, 2007

Where have all the billions gone?
Long time passing
Where have all the billions gone?
Long time ago
Where have all the billions gone?
Pharma has spent them every one
When will they ever learn?
When will they ever learn?

(Sing to the tune of “Where Have All the Flowers Gone?”–with apologies to Pete Seeger.)

For years, large pharmaceutical companies have mostly shied away from buying biotech companies. They have preferred to develop their own drug pipelines and to license or colicense new meds in development at biotech companies. The common wisdom has been that biotechs are nimbler and more creative than the lumbering giants, which have used the smaller companies as a kind of farm-team system to feed new compounds to the big leagues.

This trend began to shift last year when Novartis purchased Chiron, and Merck of Germany bought Serano. Now Astra-Zeneca has snatched up Medimmune for $15.6 billion, in what may be the largest purchase ever of a U.S. biotechnology company.

This is not a financial blog, so I won’t bore you with finance-speak or details about companies you may or may not have heard of. The point is that folding the best of biotech into large companies that are having serious trouble developing their own drugs may be a great idea for investors cashing in, but it may end up killing off creativity in drug making.

It’s hard to imagine that huge companies, spending billions on R&D with little to show for it, will absorb the creativity and entrepreneurial drive of the smaller companies. Maybe they will, though this seems to be less a motivation for new ideas than a fear of what these companies might do.

In 2005, Big Pharma companies spent $40 billion on R&D in a year in which the FDA approved only 20 drugs. Comparatively, in 1996, $17 billion was spent, and 53 new drugs were approved. Add to this the fact that many billion-dollar drugs are about to lose their patent protection on blockbuster drugs such as Lipitor, and one can understand why Big Pharma is throwing around money while it still has it.

Possibly, these bioyoungsters will infuse new blood into their elders rather than the other way around. Otherwise, we may see the pharmaceutical industry continuing to be unable to transform the raft of discoveries and science developed in the past 10 years into useful products.

There are many reasons for this failure, not the least of which is that the science is turning out to be far more difficult to turn into drugs than anyone anticipated in this age of genomics. But one still has to wonder if the industry is up to the task in its current incarnation.

Become an MIT Technology Review Insider for in-depth analysis and unparalleled perspective.

Subscribe today
Want more award-winning journalism? Subscribe and become an Insider.
  • Insider Plus {! insider.prices.plus !}* Best Value

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    Print + Digital Magazine (6 bi-monthly issues)

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

    Technology Review PDF magazine archive, including articles, images, and covers dating back to 1899

    10% Discount to MIT Technology Review events and MIT Press

    Ad-free website experience

  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning print magazine, unlimited online access plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    Print Magazine (6 bi-monthly issues)

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

  • Insider Online Only {! insider.prices.online !}*

    {! insider.display.menuOptionsLabel !}

    Unlimited online access including articles and video, plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.